Andrew Haydon Clinical Oncology Society of Australia Annual Scientific Meeting 2023

Abstracts this author is presenting:

• COLUMBUS 7-Year Update: A Randomised, Open-Label, Phase 3 Trial of Encorafenib (Enco) + Binimetinib (Bini) vs Vemurafenib (Vemu) or Enco in Patients (Pts) With BRAF V600–Mutant Melanoma — Lunch, Poster Viewing, Exhibition & COSA Group Meetings